<DOC>
	<DOCNO>NCT02794220</DOCNO>
	<brief_summary>The purpose study ass amount nicotine absorb blood stream follow use new Electronic Cigarette device call CN electronic cigarette . The amount nicotine deliver via CN electronic cigarette compare amount nicotine deliver smoking regular cigarette use NicoretteÂ® Inhalator . Electronic cigarettes aim mimic experience cigarette smoking , deliver nicotine rapidly . Unlike cigarette however , contain many harmful combustion product contain tobacco smoke . Electronic cigarettes readily available many market , may contain significant quantity nicotine . However , regulate medicine , manufacturer make medicinal claim . Such product unregulated , subject regulatory review either Medicines Healthcare Products Regulatory Agency ( MHRA ) Notified Body . It intention CN Creative ( maker CN electronic cigarette ) submit application MHRA CN Electronic Cigarette , order make high quality , regulate product available . Males age 18-65 , smoke intention stop smoke trial eligible take part study . The study consist screen visit , treatment period 5 overnight stay nicotine treatment day 1 , 2 , 3 4 post study visit day 5 .</brief_summary>
	<brief_title>A Study Blood Levels Nicotine Following Electronic Cigarette</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<criteria>Provision sign write informed consent . Males age 1865 year . Subject Body Mass Index ( BMI ) 1830 Body Mass Index = Body weight ( kg ) / [ Height ( ) ] 2 . Regular moderate cigarette smoker ( approximately 10 20 cigarette per day least 5 year ) intend make quit attempt study . No obvious symptom ill health determine prestudy medical examination ( perform within 4 week first dose ) . Subject clinically significant abnormality 12lead electrocardiogram ( ECG ) , include normal rest ECG QTcB interval le 440 m determine within 4 week first dose . No clinically significant abnormality blood pressure value ( difference supine stand BP le 20 mmHg ) symptomatic evidence postural hypotension . Subject clinically significant abnormal serum biochemistry , haematology urine examination value within 4 week first dose . Subject negative urinary drug abuse screen ( exclude nicotine ) , determine within 4 week first dose ( N.B . positive alcohol result may repeat discretion Investigator ) . Subject negative HIV Hepatitis B C result . To reconfirm Day 0 : Subject continue meet screen inclusion criterion . Subject negative urinary drug abuse screen ( include alcohol ) prior dose To confirm Screening Visit : Evidence renal , hepatic , central nervous system , respiratory ( include COPD ) , cardiovascular metabolic dysfunction . Known allergy ingredient study medication . A history current drug alcohol abuse . Inability communicate well Investigator/study staff ( i.e. , language problem , poor mental development impair cerebral function ) . Participation New Chemical Entity clinical study within previous 4 month market drug clinical study within previous 3 month ( N.B . washout period trial define period time elapse last dose previous study first dose next study.. Donation 450ml blood within previous 3 month . Any clinically significant medical history , theInvestigator 's opinion , include condition might affect drug absorption , metabolism excretion . Unlikely comply trial visit schedule trial medication dosing requirement . Severe intercurrent illness , opinion Investigator , may put subject risk participate trial may influence result trial affect subject ' ability take part trial . Excessive intake alcohol , define regular maximum weekly intake great 28 unit men ( 1 unit equal half pint beer , 1 small glass wine 1 x 25 mL measure spirit ) within last 6 month . Treatment smoke cessation medication ( bupropion , Champix , NRT ) within 8 week plan first nicotine dose occasion . Treatment prescription medication within 21 day overthecounter medication within 72 hour plan first nicotine dose occasion . Clinical judgement Investigator subject participate study reason . To confirm Day 0 : Development exclusion criterion since screen Receipt medication since screen visit may impact safety objective study ( Investigator 's discretion ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>E-cigarette</keyword>
	<keyword>healthy volunteer study</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Nicorette</keyword>
</DOC>